Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Arsenic trioxide - Teva Pharmaceutical Industries

Drug Profile

Arsenic trioxide - Teva Pharmaceutical Industries

Alternative Names: NSC-706363; Trisenox

Latest Information Update: 21 Sep 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CTI BioPharma
  • Developer Leukemia SPORE; Northwestern University; Temple University; Teva Pharmaceutical Industries; University of Texas M. D. Anderson Cancer Center
  • Class Anti-inflammatories; Antineoplastics; Arsenicals; Ischaemic heart disorder therapies; Oxides; Small molecules
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma; Myelodysplastic syndromes; Liver cancer; Chronic myeloid leukaemia; Acute myeloid leukaemia; Acute promyelocytic leukaemia; Glioma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute promyelocytic leukaemia
  • Phase II Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Phase I/II Glioma
  • Discontinued Multiple myeloma

Most Recent Events

  • 06 Aug 2018 National Institutes of Health and Teva Pharmaceuticals terminates a phase I trial for Chronic myeloid leukaemia (second-line therapy or greater, combination thereapy) in USA (NCT01397734)
  • 08 May 2018 The National Institute for Health and Care Excellence in the UK recommended arsenic trioxide for Acute promyelocytic leukaemia
  • 15 Jan 2018 Registered for Acute promyelocytic leukaemia (Combination therapy, Newly diagnosed) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top